Introduction Patients with type 2 diabetes have an increased risk of developing adverse
cardiovascular (CV) outcomes. The evidence relating to the effects of glucose-lowering
medications on CV outcomes is of variable quality and there are numerous trials ongoing.
Results In this review, we summarise the available literature on CV outcomes of the
following diabetes treatments: metformin, the sulfonylureas, acarbose, glucagon-like peptide
1 (GLP1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose co …